JW PharmaceuticalJW중외제약

JW Pharmaceutical's trailing profits have risen sharply while its share price has fallen over the past month.

On trailing twelve-month figures to H1 2026, the company reported revenue of about ₩821B and net income of about ₩101B, a 12.3% net margin. The shares closed at ₩23,900 on 23 October 2026, down 11% over one month but up 3.9% over one year, and sit well below the 52-week high of ₩39,250. The company profile and news headlines are not included in the data, so the business description is limited to the financial and filing figures.

What stands out

• Trailing operating margin is 13.9% and ROE is 27.4%, both above the 2025 full-year levels of 12.2% and 17.6%.
• Net income for 2025 was ₩61.5B, and the trailing figure to H1 2026 is about ₩101B, a substantial step up.
• Valuation is low on the data given: P/E 5.8, P/B 1.4 and a 2.7% dividend yield, while the DCF base case is ₩52,434 against the ₩23,900 close.
• Foreign ownership fell from 8.9% to 7.7% over about 60 days, and the 20-day flows show foreign and institutional net buying offset by retail net selling.
• Recent filings include several fines notices, a share acquisition in another company on 29 September, and a shareholder-holding change on 17 September.

What to watch

• Whether the fines matters and the amended fines filings are material, as their details are not in the data.
• Details of the share acquisition in another company and what it means for the balance sheet, given liabilities at 61% of equity and borrowings of about ₩50B.
• Next results releases, and whether the trailing profit improvement holds, since the data gives no forward forecasts.